We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMhp Reg S Regulatory News (MHPC)

Share Price Information for Mhp Reg S (MHPC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.28
Bid: 3.23
Ask: 3.28
Change: -0.05 (-1.50%)
Spread: 0.05 (1.548%)
Open: 3.28
High: 3.28
Low: 3.28
Prev. Close: 3.33
MHPC Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Consent Solicitation

15 Oct 2018 12:43

RNS Number : 0725E
MHP SE
15 October 2018
 

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

October 15, 2018

MHP SE ANNOUNCES RESULTS OF ITS CONSENT SOLICITATION

MHP SE

(a European Public Limited Liability Company (Societas Europaea) registered in Cyprus, with registered office at 16-18 Zinas Kanther Street, Ayia Triada, 3035 Limassol, Cyprus, with Registration Number SE 27)

Results of Solicitation of Consents to amend the Indenture dated as of April 2, 2013 (as supplemented by the supplemental indenture dated as of March 8, 2016) in relation to theU.S.$750,000,000 8.25% Notes due 2020 issued by MHP SERegulation S Notes: Common Code 078395044/ ISIN USL6366MAC75/ CUSIP L6366MAC7Rule 144A Notes: Common Code 078395079/ ISIN US55302TAC99/ CUSIP 55302TAC9

MHP SE (the "Company") today announces the results of its consent solicitation (the "Consent Solicitation") to seek the consent of holders (the "Holders") of the outstanding U.S.$79,417,000 8.25% Notes due 2020 issued by the Company (Regulation S Notes: Common Code 078395044/ ISIN USL6366MAC75/ CUSIP L6366MAC7; Rule 144A Notes: Common Code 078395079/ ISIN US55302TAC99/ CUSIP 55302TAC9) (the "Notes") pursuant to an indenture dated as of April 2, 2013 (as supplemented by a supplemental indenture dated as of March 8, 2016), between the Company, Citibank, N.A., London Branch, as trustee (the "Trustee"), transfer agent, paying agent and exchange agent, Citigroup Global Markets Europe AG (formerly known as Citigroup Global Markets Deutschland AG), as registrar (the "Registrar") and Deutsche Bank Trust Company Americas (the "Note Security Agent") (the "Indenture") to certain proposed amendments (the "Amendments") to the Indenture and the Notes (such solicitation, as may be amended from time to time.

The Consent Solicitation and the Amendments were announced on September 20, 2018, and were made on the terms and subject to the conditions contained in the Consent Solicitation Memorandum prepared by the Company dated September 20, 2018 (the "Consent Solicitation Memorandum"). Capitalized terms used but not otherwise defined in this announcement have the meanings given in the Consent Solicitation Memorandum.

Pursuant to an announcement on October 5, 2018, the Consent Expiration Date was amended to be 5:00 p.m. (New York time) on October 12, 2018 (the "New Expiration Time"), the Consent Settlement Date was amended to be October 17, 2018 (the "New Consent Settlement Date") and the amount of the Consent Payment was amended to be U.S.$10.00 for each U.S.$1,000 in principal amount of the Notes (the "New Consent Payment").

The Company now announces that the Requisite Consents of the Holders to implement the Amendments were obtained before the New Expiration Time and the Effective Time occurred at 5:00 p.m. New York City time on October 12, 2018. The Amendments will be implemented by way of execution of the Supplemental Indenture on October 15, 2018, provided that the Amendments shall not become effective until the New Consent Settlement Date.

The New Consent Payments will be paid by the Company on the New Consent Settlement Date which will take place on October 17, 2018. The obligation of the Company to pay the New Consent Payment will be discharged by depositing with DTC the amount of cash necessary to pay the New Consent Payment in respect of all Consents validly received and not revoked on or prior to the New Expiration Time.

The Notes in relation to which Consents were delivered pursuant to the Consent Solicitation will be unblocked as soon as practicable as described in the Consent Solicitation Memorandum, but no later than three business days after the New Expiration Time.Requests for all information in relation to the Consent Solicitation should be directed to:

The Solicitation Agent

J.P. Morgan Securities plc

25 Bank Street

Canary Wharf

London

E14 5JP

United Kingdom

Attention: Liability Management

Telephone: +44 (0) 207 134 2468

Email: em_europe_lm@jpmorgan.com

The Information and Tabulation Agent

D.F. King Ltd.

Email: mhp@dfkingltd.com

Website: https://sites.dfkingltd.com/mhp

 

In New York

48 Wall Street - 22nd FloorNew York, New York 10005Banks and Brokers Call: +1 212 269 5550All others call toll free: +1 800 848 3405

In London

125 Wood StreetLondon, EC2V 7ANTel:+44 20 7920 9700

 

In Hong Kong

Suite 1601, 16/F, Central Tower28 Queen's Road CentralHong KongTel: +852 3953 7231

 

Neither this announcement nor the Consent Solicitation Memorandum constitutes or forms part of, and should not be construed as, an offer for sale or subscription of, or a solicitation of any offer to buy or subscribe for, any securities of the Company or any other entity in any jurisdiction.

 

The distribution of this announcement and the Consent Solicitation Memorandum in certain jurisdictions may be restricted by law. Persons into whose possession this announcement or the Consent Solicitation Memorandum comes are required by the Company, the Solicitation Agent and the Information and Tabulation Agent to inform themselves about, and to observe, any such restrictions. This announcement and any materials relating to the Consent Solicitation do not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law.

 

The Notes have not been registered under the U.S. Securities Act of 1933 (the "Securities Act") or the securities law of any state or jurisdiction of the United States and may not be reoffered or resold except pursuant to an applicable exemption from the registration requirements of the Securities Act. Neither the SEC nor any U.S. state securities commission has approved or disapproved of any Notes, or determined if the Consent Solicitation Memorandum is accurate or complete. Any representation to the contrary is a criminal offence.

 

The communication of the Consent Solicitation Memorandum and this announcement by the Company and any other documents or materials relating to the Consent Solicitation are not being made, and such documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the Financial Services and Markets Act 2000 (the "FSMA"). Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. Such documents and/or materials are only directed at and may only be communicated to (1) persons who have professional experience in matters relating to investments falling within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (2) high net worth entities falling within Article 49(2)(a) to (d) of the Order, and (3) any other persons to whom these documents and/or materials may lawfully be communicated (all such persons together being referred to as "relevant persons"). Any person who is not a relevant person should not act or rely on this communication or any of its contents. Nothing in this announcement constitutes or contemplates an offer to buy or the solicitation of an offer to sell securities in the United States or in any other jurisdiction.

 

Neither the Consent Solicitation Memorandum nor any documents or materials relating to the Consent Solicitation, including this announcement (collectively referred to as the "Consent Documents") have been submitted to the approval or is intended to be submitted to the approval of the Cyprus Securities and Exchange Commission and consequently the Consent Solicitation Memorandum nor any other Consent Documents will not be distributed, released, published, communicated, advertised or disseminated, whether directly or indirectly, to the information distribution channels or to the public in Cyprus.

 

The communication of the Consent Solicitation Memorandum and of the Consent Documents in Cyprus may be made to and directed only at "professional clients", by a duly licensed investment firm or credit institution (authorized under Directive 2013/36/EU), permitted and authorised to conduct such activities in Cyprus and in accordance with the provisions of (i) the Investment Services and Activities and Regulated Markets Law, No. 144 (I) of 2007, as amended (ii) the Investment Services and Activities and Regulated Markets Law, No. 87(I)/2017, as amended from time to time; and (iii) Regulation (EU) No. 600/2014 of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Regulation (EU) No. 648/2012.

 

If a jurisdiction requires that the Consent Solicitation be made by a licensed broker or dealer and the Solicitation Agent or any of its affiliates is such a licensed broker or dealer in that jurisdiction, the Consent Solicitation shall be deemed to be made by the Solicitation Agent or such affiliates, as the case may be, on behalf of the Company in such jurisdiction where it/they is/are so licensed and the Consent Solicitation is not being made in any such jurisdiction where the Solicitation Agent or one of its affiliates are not so licensed.

 

Statements contained herein may constitute "forward-looking statements". Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "aim", "plan", "expect", "anticipate", "estimate", "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology.

 

Forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company does not undertakes publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.

 

Note: This announcement contains "regulated information" for the purposes of the EU Transparency Directive (Directive 2004/109/EC of the European Parliament and of the Council of 15 December 2004) and the Cyprus Transparency Law (Law No. 190(I)/2007). In addition, the European Union Market Abuse Regulation (Regulation EU 596/2014 of the European Parliament and of the Council of 16 April 2014) requires the Company to disclose that this announcement contains "inside information", as defined in the European Union Market Abuse Regulation.

 

Please address any questions or concerns to :

Anastasiya Sobotyuk

Director of IR

+38 044 207 00 70

+38 050 339 29 99

a.sobotyuk@mhp.com.ua

 

 

 

This announcement has been issued through the Companies Announcement Service of Euronext Dublin.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ISEDMMMGMKGGRZM
Date   Source Headline
11th Mar 20241:02 pmRNSEGM Results
7th Feb 202412:41 pmRNSEGM- Convening Notice
23rd Jan 20249:54 amRNSAppointment of a new ARC Chair
16th Nov 20237:13 amRNSQ3 and 9M 2023 Financial Results
25th Sep 20239:02 amRNSFinancial Statement Q2 2023
21st Sep 20237:06 amRNSDate Notification Q2 2023 Results
8th Sep 20237:00 amRNSMHP SE Invests in Saudi Arabia
19th Jun 20238:41 amRNSAGM results
18th May 20237:00 amRNSQ1 2023 Financial and Operational Results
17th May 202311:00 amRNSAGM Convening Notice
11th Apr 20239:42 amRNSMHP SE Standalone FS 2022
11th Apr 20239:27 amRNSMHP SE Standalone FS 2022
11th Apr 20238:54 amRNSMHP SE Standalone 2022
11th Apr 20237:00 amRNS2022 Integrated Annual Report
21st Mar 202311:07 amRNSDate Notification - Date Change
7th Mar 202310:24 amRNSEGM results
16th Feb 20231:54 pmRNSMHP and Tanmiah - announcement of a partnership
2nd Feb 20237:25 amRNSConvening Notice - EGM
25th Jan 20237:53 amRNSMonthly Operational Update - December 2022
17th Jan 20234:41 pmRNSSecond Price Monitoring Extn
17th Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Dec 20227:00 amRNSMonthly Operational Update - November 2022
25th Nov 20228:00 amRNSMonthly Operational Update - October 2022
16th Nov 20227:00 amRNSQ3 and 9M 2022 Financial and Operational Results
25th Oct 20227:00 amRNSMonthly Operational Update - September
23rd Sep 20227:19 amRNSOperational Monthly Update - August 2022
14th Sep 20227:00 amRNSQ2 and H1 2022 Financial Results
2nd Sep 202212:40 pmRNSDate Change Notification
19th Aug 202210:20 amRNSOperational Monthly Update - July 2022
9th Aug 20224:41 pmRNSSecond Price Monitoring Extn
9th Aug 20224:36 pmRNSPrice Monitoring Extension
27th Jul 20227:13 amRNSQ2 and H1 2022 Pre close trading update
22nd Jul 20227:21 amRNSOperational Monthly Update - June 2022
30th Jun 20222:22 pmRNS2021 MHP Sustainability Report
24th Jun 20227:27 amRNSMHP Monthly Update - May 2022
17th Jun 20227:56 amRNSQ1 2022 Financial Results
24th May 20227:44 amRNSMonthly Operational Update for April 2022
17th May 202212:25 pmRNSAGM - Convening Notice
5th May 202212:06 pmRNSSeparate FS
5th May 202210:57 amRNSFinancial Results for the Q4 and 12M 2021
28th Apr 202210:16 amRNSDate notification
22nd Apr 20229:43 amRNSPre-Close TU for the Q1 2022
11th Apr 202210:48 amRNSMHP - Operational Update
30th Mar 20223:55 pmRNSConsent Solicitation - Results Announcement
23rd Mar 20221:40 pmRNSUpdate Announcement - Consent Solicitation
21st Mar 202210:49 amRNSMHP - Consent Solicitation Announcement
18th Mar 20221:57 pmRNSCoupon Payment Information
14th Mar 20229:41 amRNSDamage to Warehouse - Loss of Produce
10th Mar 20228:26 amRNSMHP - SUPPORT FOR UKRAINE
7th Mar 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.